Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
XPhyto Therapeutics (XPHY.C) announced today that its Good Manufacturing Practice (GMP) mescaline synthesis program is on schedule with the completion of initial production batches. Read full article here: https://equity.guru/2021/06/08/xphyto-therapeutics-xhpy-c-provides-progress-report-on-mescaline-program/
